Progress in developing virus-like particle influenza vaccines

Expert Review of Vaccines

Volumn 15, Issue 10, 2016, Pages 1281-1293

  Quan, Fu Shi ^a   Lee, Young Tae ^b   Kim, Ki Hye ^b   Kim, Min Chul ^b,c   Kang, Sang Moo ^b  

^a Kyung Hee University Hospital   (South Korea)

^b GEORGIA STATE UNIVERSITY   (United States)

^c Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

cross protection; Influenza virus; strain specific protection; vaccines; virus like particles

Indexed keywords

INFLUENZA VACCINE; VIRUS LIKE PARTICLE VACCINE;

AVIAN INFLUENZA VIRUS; CROSS PROTECTION; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW; VACCINE PRODUCTION; VIRUS LIKE AGENT; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; HUMAN; IMMUNOLOGY; ISOLATION AND PURIFICATION; TRENDS;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; INFLUENZA VACCINES; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84965048029     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2016.1175942     Document Type: Review

References (88)

1. W.W.Thompson, D.K.Shay, E.Weintraub, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179–186.
2. J.Dushoff, J.B.Plotkin, C.Viboud, et al. Mortality due to influenza in the United States–an annualized regression approach using multiple-cause mortality data. Am J Epidemiol. 2006 Jan 15;163(2):181–187.
3. S.Tong, X.Zhu, Y.Li, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9(10):e1003657.
4. G.Neumann, T.Noda, Y.Kawaoka Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009 Jun 18;459(7249):931–9002E.
5. R.Gao, B.Cao, Y.Hu, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med. 2013 May 16;368(20):1888–1897.
6. L.F.Fries, G.E.Smith, G.M.Glenn. A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med. 2013 Dec 26;369(26):2564–2566.
7. R.A.Bright, D.M.Carter, S.Daniluk, et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine. 2007 May 10;25(19):3871–3878.
8. M.J.Hossain, M.Bourgeois, F.S.Quan, et al. Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza. Clinical Vaccine Immunol:CVI. 2011 Dec;18(12):2010–2017.
9. F.S.Quan, C.Huang, R.W.Compans, et al. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol. 2007 Apr;81(7):3514–3524.
10. F.S.Quan, D.Steinhauer, C.Huang, et al. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine. 2008 Jun 19;26(26):3352–3361.
11. B.Z.Wang, F.S.Quan, S.M.Kang, et al. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J Virol. 2008 Dec;82(23):11813–11823.
12. T.M.Ross, K.Mahmood, C.J.Crevar, et al. A trivalent virus-like particle vaccine elicits protective immune responses against seasonal influenza strains in mice and ferrets. PLoS One. 2009;4(6):e6032.• A well comparison study of immunogenicity and efficacies between trivalent VLP and commercial trivalent inactivated vaccines.
13. F.S.Quan, D.G.Yoo, J.M.Song, et al. Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination. J Virol. 2009 May;83(9):4489–4497.
14. F.S.Quan, A.Vunnava, R.W.Compans, et al. Virus-like particle vaccine protects against 2009 H1N1 pandemic influenza virus in mice. PLoS One. 2010;5(2):e9161.
15. F.S.Quan, Y.C.Kim, A.Vunnava, et al. Intradermal vaccination with influenza virus-like particles by using microneedles induces protection superior to that with intramuscular immunization. J Virol. 2010 Aug;84(15):7760–7769.
16. B.Z.Wang, R.Xu, F.S.Quan, et al. Intranasal immunization with influenza VLPs incorporating membrane-anchored flagellin induces strong heterosubtypic protection. PLoS One. 2010;5(11):e13972.
17. F.S.Quan, M.C.Kim, B.J.Lee, et al. Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology. 2012 Sep 1;430(2):127–135.
18. Giles BM, Bissel SJ, Craigo JK, Dealmeida DR, Wiley CA, Tumpey TM, et al. Elicitation of anti-1918 influenza virus immunity early in life prevents morbidity and lower levels of lung infection by 2009 pandemic H1N1 influenza virus in aged mice. J Virol. 2012 Feb;86(3):1500–1513.
19. D.H.Lee, S.W.Bae, J.K.Park, et al. Virus-like particle vaccine protects against H3N2 canine influenza virus in dog. Vaccine. 2013 Jul 11;31(32):3268–3273.
20. F.Rezaei, A.Mirshafiey, S.Shahmahmoodi, et al. Influenza virus-like particle containing two different subtypes of hemagglutinin confers protection in mice against lethal challenge with A/PR8 (H1N1) and A/HK (H3N2) viruses. Iran Red Crescent Med J. 2013 Jan;15(1):75–82.
21. F.S.Quan, E.J.Ko, Y.M.Kwon, et al. Mucosal adjuvants for influenza virus-like particle vaccine. Viral Immunol. 2013 Dec;26(6):385–395.
22. J.M.Galarza, T.Latham, A.Cupo. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005;18(1):244–251.
23. P.Pushko, T.Kort, M.Nathan, et al. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine. 2010 Jul 5;28(30):4771–4776.
24. H.M.Pyo, A.Masic, N.Woldeab, et al. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs. Vaccine. 2012 Feb 8;30(7):1297–1304.
25. K.S.Inn, G.J.Lee, F.S.Quan. A pandemic H1N1 influenza virus-like particle vaccine induces cross-protection in mice. Immunol Invest. 2014;43(3):236–254.
26. L.M.Schwartzman, A.L.Cathcart, L.M.Pujanauski, et al. An intranasal virus-like particle vaccine broadly protects mice from multiple subtypes of Influenza A virus. MBio. 2015;6(4):e01044.
27. P.Pushko, T.M.Tumpey, F.Bu, et al. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine. 2005 Dec 30;23(50):5751–5759.
28. P.Pushko, T.M.Tumpey, N.Van Hoeven, et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine. 2007 May 22;25(21):4283–4290.
29. D.Matassov, A.Cupo, J.M.Galarza. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol. 2007 Sep;20(3):441–452.
30. R.A.Bright, D.M.Carter, C.J.Crevar, et al. Cross-clade protective immune responses to Influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One. 2008;3(1):e1501.• A study that describes details on homologous and heterologous protection by H5N1 influenza VLPs.
31. K.Mahmood, R.A.Bright, N.Mytle, et al. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine. 2008 Oct 3;26(42):5393–5399.
32. C.J.Crevar, T.M.Ross. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine. Virol J. 2008;5:131.
33. S.M.Kang, D.G.Yoo, A.S.Lipatov, et al. Induction of long-term protective immune responses by influenza H5N1 virus-like particles. PLoS One. 2009;4(3):e4667.
34. P.Tao, M.Luo, D.Zhu, et al. Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice. Viral Immunol. 2009 Jul;22(4):273–281.
35. Haynes JR, Dokken L, Wiley JA, Cawthon AG, Bigger J, Harmsen AG, et al. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge. Vaccine. 2009 Jan 22;27(4):530–541.
36. L.A.Perrone, A.Ahmad, V.Veguilla, et al. Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge. J Virol. 2009 Jun;83(11):5726–5734.
37. C.Y.Wu, Y.C.Yeh, Y.C.Yang, et al. Mammalian expression of virus-like particles for advanced mimicry of authentic influenza virus. PLoS One. 2010;5(3):e9784.• A study reporting the production and characterization of influenza VLPs in mammalian cells.
38. J.M.Song, J.Hossain, D.G.Yoo, et al. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology. 2010 Sep 15;405(1):165–175.
39. J.M.Song, N.Van Rooijen, J.Bozja, et al. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):757–761.
40. D.H.Lee, J.K.Park, Y.N.Lee, et al. H9N2 avian influenza virus-like particle vaccine provides protective immunity and a strategy for the differentiation of infected from vaccinated animals. Vaccine. 2011 May 23;29(23):4003–4007.
41. J.K.Park, D.H.Lee, H.N.Youn, et al. Protective efficacy of crude virus-like particle vaccine against HPAI H5N1 in chickens and its application on DIVA strategy. Influenza Other Respi Viruses. 2013 May;7(3):340–348.
42. F.Schmeisser, J.E.Adamo, B.Blumberg, et al. Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase. Vaccine. 2012 May 14;30(23):3413–3422.
43. Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clinical Vaccine Immunol:CVI. 2012 Feb;19(2):128–139.
44. I.Tretyakova, M.B.Pearce, R.Florese, et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses. Virology. 2013 Jul 20;442(1):67–73.
45. J.G.Choi, M.C.Kim, H.M.Kang, et al. Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens. Vet Microbiol. 2013 Mar 23;162(2–4):623–630.
46. X.Li, P.Pushko, I.Tretyakova. Recombinant hemagglutinin and virus-like particle vaccines for H7N9 influenza virus. J Vaccines Vaccin. 2015 Jun;6(3). doi:10.4172/2157-7560.1000287.
47. K.Y.Chung, E.M.Coyle, D.Jani, et al. ISCOMATRIX adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans. Vaccine. 2015 Jul 31;33(32):3953–3962.•• A study of clinical trials proving the advantages of timing and efficacy of pandemic potential H7N9 influenza VLP vaccines.
48. Y.V.Liu, M.J.Massare, M.B.Pearce, et al. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets. Vaccine. 2015 Apr 27;33(18):2152–2158.
49. Z.Ren, X.Ji, L.Meng, et al. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus. Virus Res. 2015 Mar 16;200:9–18.
50. C.Xue, G.Tian, X.Chen, et al. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens. Virus Res. 2015 Jan;2(195):35–42.
51. W.A.Rodriguez-Limas, K.Sekar, K.E.Tyo. Virus-like particles:the future of microbial factories and cell-free systems as platforms for vaccine development. Curr Opin Biotechnol. 2013 Dec;24(6):1089–1093.
52. A.Zeltins. Construction and characterization of virus-like particles:a review. Mol Biotechnol. 2013 Jan;53(1):92–107.
53. J.M.Song, B.Z.Wang, K.M.Park, et al. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One. 2011;6(1):e14538.
54. T.Latham, J.M.Galarza. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol. 2001 Jul;75(13):6154–6165.• A report that well describes the concept of producing influenza VLPs in insect cells.
55. T.V.Komarova, S.Baschieri, M.Donini, et al. Transient expression systems for plant-derived biopharmaceuticals. Expert Rev Vaccines. 2010 Aug;9(8):859–876.• A review article covering the development of recombinant vaccines produced by using the plant cell expression system.
56. W.P.Kong, C.Hood, Z.Y.Yang, et al. Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. PNAS. 2006 Oct 24;103(43):15987–15991.
57. M.C.Kim, J.W.Lee, H.J.Choi, et al. Microneedle patch delivery to the skin of virus-like particles containing heterologous M2e extracellular domains of influenza virus induces broad heterosubtypic cross-protection. Journal Controlled Release:Off J Controlled Release Soc. 2015 Jul 28;210:208–216.
58. B.Dubois, C.Massacrier, C.Caux. Selective attraction of naive and memory B cells by dendritic cells. J Leukoc Biol. 2001 Oct;70(4):633–641.
59. H.Qi, J.G.Egen, A.Y.Huang, et al. Extrafollicular activation of lymph node B cells by antigen-bearing dendritic cells. Science. 2006 Jun 16;312(5780):1672–1676.
60. M.Wykes, A.Pombo, C.Jenkins, et al. Dendritic cells interact directly with naive B lymphocytes to transfer antigen and initiate class switching in a primary T-dependent response. J Immunol. 1998 Aug 1;161(3):1313–1319.
61. M.Del Pilar Martin, W.C.Weldon, V.G.Zarnitsyn, et al. Local response to microneedle-based influenza immunization in the skin. MBio. 2012;3(2):e00012–12.
62. M.Pearton, S.M.Kang, J.M.Song, et al. Influenza virus-like particles coated onto microneedles can elicit stimulatory effects on Langerhans cells in human skin. Vaccine. 2010 Aug 23;28(37):6104–6113.
63. B.B.Jacobs, R.A.Huseby. Growth of tumors in allogeneic hosts following organ culture explantation. Transplantation. 1967 May;5(3):410–419.
64. R.E.Billingham. The passenger cell concept in transplantation immunology. Cell Immunol. 1971 Feb;2(1):1–12.
65. R.T.Kenney, S.A.Frech, L.R.Muenz, et al. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med. 2004 Nov 25;351(22):2295–2301.
66. K.A.Pape, D.M.Catron, A.A.Itano, et al. The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. Immunity. 2007 Apr;26(4):491–502.
67. I.A.Ramshaw, A.J.Ramsay. The prime-boost strategy:exciting prospects for improved vaccination. Immunol Today. 2000 Apr;21(4):163–165.
68. V.C.Huber, R.M.McKeon, M.N.Brackin, et al. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol. 2006 Sep;13(9):981–990.
69. J.M.Patel, M.C.Kim, V.F.Vartabedian, et al. Protein transfer-mediated surface engineering to adjuvantate virus-like nanoparticles for enhanced anti-viral immune responses. Nanomed:Nanotechnol Biol Med. 2015 Jul;11(5):1097–1107.
70. F.Krammer. Emerging influenza viruses and the prospect of a universal influenza virus vaccine. Biotechnol J. 2015 May;10(5):690–701.
71. E.C.Claas, A.D.Osterhaus, R.Van Beek, et al. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet. 1998 Feb 14;351(9101):472–477.
72. J.Szecsi, B.Boson, P.Johnsson, et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J. 2006;3:70.
73. G.E.Smith, D.C.Flyer, R.Raghunandan, et al. Development of influenza H7N9 virus like particle (VLP) vaccine:homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus. Vaccine. 2013 Sep 13;31(40):4305–4313.
74. M.Klausberger, M.Wilde, D.Palmberger, et al. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine. 2014 Jan 9;32(3):355–362.
75. H.Burges, G.Croizier, J.Huber. A review of safety tests on baculoviruses. Entomopaga. 1980;25(4):329–340.
76. C.Kenoutis, R.C.Efrose, L.Swevers, et al. Baculovirus-mediated gene delivery into mammalian cells does not alter their transcriptional and differentiating potential but is accompanied by early viral gene expression. J Virol. 2006 Apr;80(8):4135–4146.
77. C.López-Macías, E.Ferat-Osorio, A.Tenorio-Calvo, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. 2011 Oct 13;29(44):7826–7834.•• A study of clinical trials demonstrating the safety and immunogenicity of 2009 H1N1 pandemic VLP vaccines.
78. S.Khurana, J.Wu, N.Verma, et al. H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans. J Virol. 2011 Nov;85(21):10945–10954.
79. M.A.D’Aoust, M.M.Couture, N.Charland, et al. The production of hemagglutinin-based virus-like particles in plants:a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J. 2010 Jun;8(5):607–619.
80. N.Landry, B.J.Ward, S.Trepanier, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One. 2010;5(12):e15559.
81. Q.Chen, H.Lai. Plant-derived virus-like particles as vaccines. Hum Vaccin Immunother. 2013 Jan;9(1):26–49.
82. J.G.Low, L.S.Lee, E.E.Ooi, et al. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine:results from a double-blinded, randomized Phase I clinical trial in healthy Asian volunteers. Vaccine. 2014 Sep 3;32(39):5041–5048.
83. A.J.McMichael, F.M.Gotch, G.R.Noble, et al. Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983 Jul 7;309(1):13–17.
84. T.M.Wilkinson, C.K.Li, C.S.Chui, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012 Feb;18(2):274–280.
85. S.Sridhar, S.Begom, A.Bermingham, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat Med. 2013 Oct;19(10):1305–1312.
86. M.C.Kim, J.M.Song, O.EO, et al. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Therapy:Journal Am Soc Gene Ther. 2013 Feb;21(2):485–492.
87. T.J.Wohlbold, R.Nachbagauer, H.Xu, et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio. 2015;6(2):e02556.
88. J.Steel, A.C.Lowen, T.Wang, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio. 2010;1:1.